OR WAIT null SECS
Significance of ADmirable Data on Lebrikizumab Use for Atopic Dermatitis in Skin of Color
This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.
At the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, the HCPLive team spoke with a trial investigator from the phase 3b ADmirable study about the impact of lebrikizumab (Ebglyss) on atopic dermatitis in adult and adolescent patients with skin of color.
The team interviewed Andrew Alexis, MD, MPH, an ADmirable investigator, professor of clinical dermatology, and vice-chair for diversity and inclusion at Weill Cornell Medicine, on the new lebrikizumab data and its significance for those with atopic dermatitis who are also patients with skin of color. Alexis was asked how he sees the ADmirable data contributing to the broader effort to improve diagnosis, treatment, and representation in atopic dermatitis care for patients with skin of color.
Alexis noted that he believes the data contribute to the overall understanding of atopic dermatitis across diverse patient populations, adding that they help to fill a historic data gap with respect to patients with skin of color. In addition, Alexis highlighted that there were many clinical photos that were taken as part of the study, which in turn could serve as educational tools and give us even further insight into the variable morphology of atopic dermatitis across different time points.
Alexis has reported advisory/consulting fees from companies including Lilly.
References
Alexis A, Moiin A, Waibel J, et al. Efficacy and safety of lebrikizumab in adult and adolescent patients with skin of color and moderate-to-severe atopic dermatitis: final 24-wWeek results from the phase 3b, open-label ADmirable study. Presented at: 2025 Revolutionizing Atopic Dermatitis (RAD) Conference; June 6-7, 2025; Nashville, TN.
FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis. September 13, 2024. Accessed June 18, 2025. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-ebglysstm-lebrikizumab-lbkz-adults-and.
